APM
Avidity Partners Management Portfolio holdings
AUM
$499M
This Quarter Return
-2.89%
1 Year Return
+3.47%
3 Year Return
+181.12%
5 Year Return
+409%
10 Year Return
–
AUM
$3.01B
AUM Growth
+$3.01B
(-30%)
Cap. Flow
-$880M
Cap. Flow
% of AUM
-29.21%
Top 10 Holdings %
Top 10 Hldgs %
32.92%
Holding
106
New
21
Increased
16
Reduced
41
Closed
22
Top Buys
| 1 |
Regeneron Pharmaceuticals
REGN
|
$97.9M |
| 2 |
Becton Dickinson
BDX
|
$71.3M |
| 3 |
Zoetis
ZTS
|
$67.8M |
| 4 |
Merck
MRK
|
$63.8M |
| 5 |
Bio-Rad Laboratories Class A
BIO
|
$61.9M |
Top Sells
| 1 |
United Therapeutics
UTHR
|
$218M |
| 2 |
argenx
ARGX
|
$128M |
| 3 |
Madrigal Pharmaceuticals
MDGL
|
$125M |
| 4 |
Boston Scientific
BSX
|
$120M |
| 5 |
Neurocrine Biosciences
NBIX
|
$97.6M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Arvinas
ARVN
$568M
| $117M | 3.88% | 4,273,900 -676,100 | -14% | -$18.5M |
|
2
Surgery Partners
SGRY
$2.91B
| $116M | 3.84% | 3,355,900 +243,900 | +8% | +$8.41M |
|
|
3
Bio-Rad Laboratories Class A
BIO
$8.06B
| $106M | 3.52% | 221,500 +129,300 | +140% | +$61.9M |
|
|
4
argenx
ARGX
$43.6B
| $105M | 3.47% | 280,700 -344,300 | -55% | -$128M |
|
5
Jazz Pharmaceuticals
JAZZ
$7.75B
| $99.2M | 3.29% | 677,900 -49,641 | -7% | -$7.26M |
|
|
6
Regeneron Pharmaceuticals
REGN
$61.5B
| $97.9M | 3.25% | +119,100 | New | +$97.9M |
|
7
Akero Therapeutics
AKRO
$3.74B
| $93.6M | 3.11% | 2,447,000 -1,378,000 | -36% | -$52.7M |
|
8
Tenet Healthcare
THC
$16.3B
| $87.5M | 2.9% | 1,472,000 +754,700 | +105% | +$44.8M |
|
9
Ultragenyx Pharmaceutical
RARE
$2.89B
| $85.3M | 2.83% | 2,126,900 -863,100 | -29% | -$34.6M |
|
10
Universal Health Services
UHS
$11.6B
| $85.2M | 2.83% | 670,000 -155,600 | -19% | -$19.8M |
|
11
Acadia Healthcare
ACHC
$2.12B
| $84.2M | 2.79% | 1,165,300 +300 | +0% | +$21.7K |
|
|
12
Neurocrine Biosciences
NBIX
$13.8B
| $82.6M | 2.74% | 815,700 -964,300 | -54% | -$97.6M |
|
13
Syndax Pharmaceuticals
SNDX
$1.41B
| $81.6M | 2.71% | 3,865,300 -1,995,700 | -34% | -$42.1M |
|
|
KRTX
14
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $73.3M | 2.43% | 403,800 +104,800 | +35% | +$19M |
|
|
15
Becton Dickinson
BDX
$55.3B
| $71.3M | 2.37% | +288,000 | New | +$71.3M |
|
16
Pliant Therapeutics
PLRX
$101M
| $70.9M | 2.35% | 2,665,000 +424,600 | +19% | +$11.3M |
|
|
17
Zoetis
ZTS
$69.3B
| $67.8M | 2.25% | +407,500 | New | +$67.8M |
|
18
Ventyx Biosciences
VTYX
$171M
| $64.2M | 2.13% | 1,917,800 +632,800 | +49% | +$21.2M |
|
|
19
Merck
MRK
$210B
| $63.8M | 2.12% | +600,000 | New | +$63.8M |
|
20
Sarepta Therapeutics
SRPT
$1.78B
| $57.3M | 1.9% | 416,000 -639,000 | -61% | -$88.1M |
|
21
Legend Biotech
LEGN
$6.41B
| $54M | 1.79% | 1,120,500 +150,500 | +16% | +$7.26M |
|
22
Prothena Corp
PRTA
$441M
| $51.8M | 1.72% | 1,068,200 -1,884,800 | -64% | -$91.4M |
|
23
IDEAYA Biosciences
IDYA
$2.15B
| $50.4M | 1.67% | 3,673,400 -151,400 | -4% | -$2.08M |
|
24
Zentalis Pharmaceuticals
ZNTL
$122M
| $50.4M | 1.67% | 2,929,300 -2,220,700 | -43% | -$38.2M |
|
|
ISEE
25
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $45.5M | 1.51% | 1,869,200 +1,030,793 | +123% | +$25.1M |
|